211 related articles for article (PubMed ID: 32603203)
1. Mometasone furoate-loaded aspasomal gel for topical treatment of psoriasis: formulation, optimization,
Shinde G; Desai P; Shelke S; Patel R; Bangale G; Kulkarni D
J Dermatolog Treat; 2022 Mar; 33(2):885-896. PubMed ID: 32603203
[TBL] [Abstract][Full Text] [Related]
2. Topical Nanostructured Lipid Carrier Based Hydrogel of Mometasone Furoate for the Treatment of Psoriasis.
Kaur N; Sharma K; Bedi N
Pharm Nanotechnol; 2018; 6(2):133-143. PubMed ID: 29788899
[TBL] [Abstract][Full Text] [Related]
3. Development of Niosomal Vesicles Loaded Mometasone Furoate Gel for Transdermal Delivery and its Evaluation.
Rane BR; Chavan PY; Kate NS; Jain AS
Recent Adv Drug Deliv Formul; 2023; 17(4):300-313. PubMed ID: 37974444
[TBL] [Abstract][Full Text] [Related]
4. Ascorbic acid derivative-loaded modified aspasomes: formulation,
Aboul-Einien MH; Kandil SM; Abdou EM; Diab HM; Zaki MSE
J Liposome Res; 2020 Mar; 30(1):54-67. PubMed ID: 30821553
[TBL] [Abstract][Full Text] [Related]
5. Development and evaluation of solid lipid nanoparticles of mometasone furoate for topical delivery.
Madan JR; Khude PA; Dua K
Int J Pharm Investig; 2014 Apr; 4(2):60-4. PubMed ID: 25006550
[TBL] [Abstract][Full Text] [Related]
6. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
Guenther LC; Poulin YP; Pariser DM
Clin Ther; 2000 Oct; 22(10):1225-38. PubMed ID: 11110233
[TBL] [Abstract][Full Text] [Related]
7. Ascorbyl palmitate vesicles (Aspasomes): formation, characterization and applications.
Gopinath D; Ravi D; Rao BR; Apte SS; Renuka D; Rambhau D
Int J Pharm; 2004 Mar; 271(1-2):95-113. PubMed ID: 15129977
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1%.
Korting HC; Schöllmann C; Willers C; Wigger-Alberti W
Skin Pharmacol Physiol; 2012; 25(3):133-41. PubMed ID: 22353786
[TBL] [Abstract][Full Text] [Related]
9. Topical treatment for scalp psoriasis: Comparison of patient preference, quality of life and efficacy for non-alcoholic mometasone emulsion versus calcipotriol/betamethasone gel in daily clinical practice.
Gual A; Pau-Charles I; Molin S
J Dermatolog Treat; 2016; 27(3):228-34. PubMed ID: 26503824
[TBL] [Abstract][Full Text] [Related]
10. Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids.
Spada F; Barnes TM; Greive KA
Australas J Dermatol; 2018 Aug; 59(3):e168-e174. PubMed ID: 29411351
[TBL] [Abstract][Full Text] [Related]
11. Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis: ex vivo-in vivo evaluation study.
Abu Hashim II; Abo El-Magd NF; El-Sheakh AR; Hamed MF; Abd El-Gawad AEH
Int J Nanomedicine; 2018; 13():1059-1079. PubMed ID: 29503541
[TBL] [Abstract][Full Text] [Related]
12. Antipsoriatic and Anti-inflammatory Studies of
Nimisha ; Rizvi DA; Fatima Z; Neema ; Kaur CD
Pharmacogn Mag; 2017 Oct; 13(Suppl 3):S587-S594. PubMed ID: 29142419
[TBL] [Abstract][Full Text] [Related]
13. Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study.
Poulin YP
Cutis; 1999 Jan; 63(1):41-8. PubMed ID: 9951595
[TBL] [Abstract][Full Text] [Related]
14. Formulation and Evaluation of Thermoreversible In Situ Nasal Gels Containing Mometasone Furoate for Allergic Rhinitis.
Altuntaş E; Yener G
AAPS PharmSciTech; 2017 Oct; 18(7):2673-2682. PubMed ID: 28281209
[TBL] [Abstract][Full Text] [Related]
15. Study on the Slow-Release Mometasone Furoate Injection of PLGA for the Treatment of Knee Arthritis.
Liang Y; Zhang J; Zhao X; Wang M; Ding S; Wang Y; Chen Y; Liu J
Curr Drug Deliv; 2021; 18(3):357-368. PubMed ID: 32940181
[TBL] [Abstract][Full Text] [Related]
16. Development and characterisation of clobetasol propionate loaded Squarticles as a lipid nanocarrier for treatment of plaque psoriasis.
Dadwal A; Mishra N; Rawal RK; Narang RK
J Microencapsul; 2020 Aug; 37(5):341-354. PubMed ID: 32293928
[No Abstract] [Full Text] [Related]
17. Design & development of nanosponge loaded topical gel of curcumin and caffeine mixture for augmented treatment of psoriasis.
Iriventi P; Gupta NV; Osmani RAM; Balamuralidhara V
Daru; 2020 Dec; 28(2):489-506. PubMed ID: 32472531
[TBL] [Abstract][Full Text] [Related]
18. Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris.
Tiplica GS; Salavastru CM
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):905-12. PubMed ID: 19470062
[TBL] [Abstract][Full Text] [Related]
19. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study.
Koo J; Cuffie CA; Tanner DJ; Bressinck R; Cornell RC; DeVillez RL; Edwards L; Breneman DL; Piacquadio DJ; Guzzo CA; Monroe EW
Clin Ther; 1998; 20(2):283-91. PubMed ID: 9589819
[TBL] [Abstract][Full Text] [Related]
20. Formulation and Optimization of Topical Solid Lipid Nanoparticles based Gel of Dapsone Using Design of Experiment.
Deshkar SS; Bhalerao SG; Jadhav MS; Shirolkar SV
Pharm Nanotechnol; 2018; 6(4):264-275. PubMed ID: 30394227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
